Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04242784 · ClinicalTrials.gov registry record

IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care

A clinical trial, sponsored by Duke University.

Completed
Registry status
21,646
Enrollment target

NCT04242784: Completed study, sponsored by Duke University.

NCT04242784 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 21,646 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04242784 has completed, sponsored by Duke University.

COMPLETED
Registry status
21,646 participants
Enrollment target

Study Summary

The purpose of this program is to develop a regional integrated stroke system that identifies, classifies, and treats patients with acute ischemic stroke more rapidly and effectively with reperfusion therapy.

Primary Outcome

The time frame starting from the earliest time that the patient is documented as arriving to the hospital to the beginning time of the administration of the drug (TPA)

Trial Details

FieldValue
Enrollment Target 21,646 participants
Start Date 2019-01-01
Est. Completion 2021-04-30
Duke University

1,725 total trials

What the finished NCT04242784 record still lists

NCT04242784 is an observational study that tracks outcomes without assigning an intervention. Its 21,646 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT04242784 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04242784 about?

NCT04242784 is a clinical study titled "IMPROVE Stroke Care- Developing and Optimizing Regional Systems of Stroke Care". The purpose of this program is to develop a regional integrated stroke system that identifies, classifies, and treats patients with acute ischemic stroke more rapidly and effectively with reperfusion therapy.

What is the current status of trial NCT04242784?

This trial is currently completed. The enrollment target is 21,646 participants. The study started on 2019-01-01. Estimated completion is 2021-04-30.

Who is sponsoring clinical trial NCT04242784?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06047041 · 21,350 participants · NA

    Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students

  • NCT05832307 · 22,000 participants · NA

    The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program

  • NCT05488080 · 22,032 participants · NA

    PAINED: Project Addressing INequities in the Emergency Department

  • NCT07413211 · 22,068 participants

    Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04242784, the US trial registry maintained by the National Library of Medicine. NCT04242784 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.